Monoamine oxidase inhibitors (MAOIs) have attracted controversy ever since they were introduced to psychiatry 30 years ago. Concern about hypertensive crises and doubts about their efficacy compared with the tricyclic antidepressives, contributed to this lack of consensus. More up-to-date studies allow a reassessment of their efficacy, and two recent editorials highlight their value.1,2
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.